{"DDN": "12/11/1974", "DateRCP": "07/02/2022", "DatePrelevement": "07/01/2022", "NaturePrelevement": "biopsie h\u00e9patique", "ResiduTumoralApresChirurgie": "X", "T": "TX", "N": "NX", "M": "M1", "Histologie": "NST grade II, RH- HER2-, PDL1 10%", "MotifRCP": "AjustementTherapeutique", "ATCD": "cancer du sein chez la m\u00e8re, tabagisme 30PA", "HDM": "2017 : cancer du sein triple n\u00e9gatif trait\u00e9 par chirurgie chimio adjuvante et radioth\u00e9rapie. Puis surveillance. 2022 : r\u00e9cidive m\u00e9tastatique h\u00e9patique au scanner, prouv\u00e9e histologiquement.", "Question": "Pembrolizumab associ\u00e9e \u00e0 la chimioth\u00e9rapie ?", "OMS": 1.0, "Decouverte": "ManifestationClinique", "PhaseMaladie": "Rechute", "DPD": "NonRealise", "TypeTT": "Immunoth\u00e9rapie", "DetailTT": "Pembrolizumab", "PhaseTT": "MiseEnTraitement", "TypeTT2": null, "TypeTT3": null}
